Abstract 457P
Background
Cancer patients have a significantly higher risk of developing venous thromboembolism (VTE) compared to the general population. But there are no data on the management of cancer associated VTE at the end of life and no guidance when to stop anticoagulation for the imminent death in hospice care.
Methods
We retrospectively reviewed 153 VTE patients with advanced cancer who were treated with anticoagulation in our hospital from January 2016 to December 2022.
Results
Total 153 patients managed with anticoagulation for the treatment and secondary prevention for cancer associated VTE were enrolled. The median age of patients with 66 years and 69% of patients were female. The median duration of treatment with anticoagulation was 92.3 days. 42% of patients were receiving prophylactic anticoagulation, most frequently low molecular weight heparin. Of these patients, 47 patients continued anticoagulation therapy until death, 22 patients up to 7 days prior to death, 14 patients up to 28 days to 8 days and 15 patients over 1 month. Clinically relevant non-major bleeding was recorded 8 patients. However, bleeding rates increased closer impending death with 6 patients of bleeding in the last 7 days of life. No data were recorded suggestive of recurrence VTE or major bleeding. Despite specialized palliative consultation, at the time of death 30% of patients were still on prophylactic anticoagulation.
Conclusions
The majority of advanced cancer patients with VTE were managed with anticoagulation up to or within days of death in real world. Patients with poor performance status and short prognosis are unlikely to benefit from anticoagulation. Given the absence of guidelines about the use of anticoagulation in terminal cancer patients, it should be an early and multidisciplinary decision. It will be a strategy to improve a rational policy of anticoagulation and to prevent bleeding complication.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
16P - Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment
Presenter: Jiun-I Lai
Session: Poster Display
Resources:
Abstract
17P - Initial outcomes of the ACT Now PRIME CARE for breast cancer: Prevention of Breast canceR (screening/ stage shifting) utilizing Integrated MobilE Clinics and pAtient Reported online Evaluations and Education
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
18P - Optimizing premenopausal HR+ HER2–ve eBC management in India: Insights from expert consensus
Presenter: Anitha Ramesh
Session: Poster Display
Resources:
Abstract
19P - Referral patterns among breast cancer patients in county-level hospitals in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
20P - Real-world treatment of HER2+ and HR+/HER2- early breast cancer in county areas of China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
21P - Duration of breast cancer trials: Analysis of predicted versus actual completion date
Presenter: Daniëlle Verschoor
Session: Poster Display
Resources:
Abstract
22P - Impact of an online Asian genetic risk calculator on risk perception: Cancer-related distress and uptake of genetic counselling among Malaysian breast cancer patients (The ARiCa Study)
Presenter: HEAMANTHAA Padmanabhan
Session: Poster Display
Resources:
Abstract
23P - Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)
Presenter: Soo Chin Lee
Session: Poster Display
Resources:
Abstract
24P - Germline genetic testing for hereditary cancer: A retrospective analysis in a single site referral centre in Malaysia
Presenter: Vivian Lee
Session: Poster Display
Resources:
Abstract
25P - Clinical presentations and prognostication of HER2-low breast cancer in Taiwan
Presenter: Bo-Fang Chen
Session: Poster Display
Resources:
Abstract